Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Voyageur PharmaceuticalsVYYRF +17.19%28 3-1 Month Momentum % is 25.00% as of Aug. 09, 2026. GuruFocus rates VYYRF with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,019 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks better than 95.98% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-09), Voyageur Pharmaceuticals's 3-1 Month Momentum % is 25.00%.
The industry rank for Voyageur Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
VYYRF's 3-1 Month Momentum % is ranked better than 95.98% of 1019
companies
in the Drug Manufacturers industry
Industry Median: -7.87
vs VYYRF: 25.00
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Voyageur Pharmaceuticals 3-1 Month Momentum % Related Terms
VYYRF vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyageur Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Voyageur Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyageur Pharmaceuticals (VYYRF) has a 3-1 Month Momentum % of 25.00% as of Aug. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Voyageur Pharmaceuticals and its competitors. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #41 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 4%.
Is Voyageur Pharmaceuticals' 3-1 Month Momentum % too high?
Voyageur Pharmaceuticals' current 3-1 Month Momentum % is 25.00%. Based on the distribution chart, Voyageur Pharmaceuticals ranks #41 out of 1019 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Voyageur Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #41 out of 1019 companies for 3-1 Month Momentum %. This places Voyageur Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Voyageur Pharmaceuticals and its competitors. Voyageur Pharmaceuticals's current 3-1 Month Momentum % is 25.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current 3-1 Month Momentum % of 25.00%. The current 3-1 Month Momentum % is 25.00%. Voyageur Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current 3-1 Month Momentum % is 25.00% as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
28GF Score
Get the complete analysis for VYYRF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYYRF has been successfully added to your 
